I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical trial design in the neoadjuvant setting for women with locally advanced breast cancer. I-SPY 2 is a collaborative effort among academic investigators, the National Cancer Institute, the US Food and Drug Administration, and the pharmaceutical and biotechnology industries under the auspices of the Foundation for the National Institutes of Health Biomarkers Consortium.
National Cancer Institute, Bethesda, Maryland, USA. barkera@mail.nih.gov
A D
AD
Barker
C C
CC
Sigman
G J
GJ
Kelloff
N M
NM
Hylton
D A
DA
Berry
L J
LJ
Esserman
D015415:Biomarkers / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D015507:Drugs, Investigational / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*
D015415:Biomarkers; D015507:Drugs, Investigational